Inhibition of AKT suppresses the initiation and progression of BRCA1-associated mammary tumors.

ABSTRACT: Despite the high incidence of BRCA1-mutant breast cancer, few substantial improvements in preventing or treating such cancers have been made. Using a Brca1-mutant mouse model, we examined the contribution of AKT to the incidence and growth of Brca1-mutated mammary tumors. A haploinsufficiency of Akt1 in Brca1-mutant mouse model significantly decreased mammary tumor formation from 54% in Brca1^co/coMMTV-Cre mice to 22% in Brca1 ^co/coMMTV-Cre Akt1^+/- mice. Notably, treatment of tumor-bearing Brca1-mutant mice with the AKT-inhibitor, MK-2206, yielded partial response or stable disease up to 91% of mice in maximum response. MK-2206 treatment also significantly reduced tumor volume and delayed recurrence in

SUBMITTER: Baek HJ 

PROVIDER: S-EPMC6231214 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature